Non-Alcoholic Steatohepatitis Treatment Market Report 2026

Non-Alcoholic Steatohepatitis Treatment Market Overview

• Non-Alcoholic Steatohepatitis Treatment market size has reached to $3.57 billion in 2025 • Expected to grow to $18.97 billion in 2030 at a compound annual growth rate (CAGR) of 39.7% • Growth Driver: Insulin Resistance Surge Fueling Growth In The Non-Alcoholic Steatohepatitis Treatment Market • Market Trend: Pioneering Endogenous Hormones In Non-Alcoholic Steatohepatitis Treatment Market • North America was the largest region in 2025.

What Is Covered Under Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis. The main drug of non-alcoholic steatohepatitis treatment are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib and cenicriviroc, obeticholic acid, and others. Vitamin E and pioglitazone in the non-alcoholic steatohepatitis treatment refers to an important fat-soluble nutrient medication needed for immune health. It is used to improve NASH by reducing oxidative stress of hepatocytes and reduce liver injury and inflammation, while pioglitazone can improve insulin sensitivity and high blood sugar levels caused by type 2 diabetes. The treatment test includes blood tests, liver biopsy, and imaging procedures, performed in hospital pharmacies, retail and specialty pharmacies, and others.

What Is The Non-Alcoholic Steatohepatitis Treatment Market Growth Forecast?

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $18.97 billion in 2030 at a compound annual growth rate (CAGR) of 39.7%. The growth in the forecast period can be attributed to advancements in precision medicine, development of novel nash drugs, adoption of digital health monitoring tools, government initiatives for liver disease prevention, increasing investment in liver disease research. Major trends in the forecast period include personalized lifestyle & diet management, non-invasive diagnostic advancements, fatty liver disease awareness programs, home-based liver health monitoring, novel pharmacological agents development.

Global Non-Alcoholic Steatohepatitis Treatment Market Segmentation

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types 2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures 3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users Subsegments: 1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations. 2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH 3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy 4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations 5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid 6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Is The Driver Of The Non-Alcoholic Steatohepatitis Treatment Market?

An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, July 2025, according to PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported that the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance increased significantly, with rates increasing from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment industry.

Key Players In The Global Non-Alcoholic Steatohepatitis Treatment Market

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Global Non-Alcoholic Steatohepatitis Treatment Market Trends and Insights

Major companies operating in the non-alcoholic steatohepatitis treatment market are developing innovative products such as endogenous hormones to meet larger customer bases, more sales, and increase revenue. Endogenous hormones are naturally occurring substances produced within the body by various glands, tissues, or organs, and they play crucial roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has given Breakthrough Therapy Designation (BTD) for Pegozafermin in individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin stands out as a distinctive product due to its engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is under development for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). What makes Pegozafermin unique is its utilization of a specialized glycoPEGylated technology, ensuring an extended half-life while preserving its potency. This innovative approach enhances the product's effectiveness in modulating key factors related to lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

What Are Latest Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market?

In September 2023, Kriya Therapeutics, a US-based biotechnology company focused on gene therapy for metabolic and neurodegenerative diseases, acquired Tramontane Therapeutics for an undisclosed amount. With this acquisition, Kriya aims to strengthen its NASH treatment pipeline by adding a one-time gene therapy program targeting Fibroblast Growth Factor 21, enhancing its technological capabilities in metabolic-liver disease therapeutics. Tramontane Therapeutics is a Spain-based biotechnology company developing gene therapy programs for metabolic and neurodegenerative diseases, including a lead candidate for non-alcoholic steatohepatitis (NASH) using AAV-mediated FGF21 expression.

Regional Insights

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Alcoholic Steatohepatitis Treatment Market Report 2026?

The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.